Caliber Imaging & Diagnostics Inc · OTC:LCDX

Caliber Imaging & Diagnostics — Investor Presentation (September 2013)

30 slides from Caliber Imaging & Diagnostics's investor presentation, September 2013

1. Slide 1: Corporate Overview

   Corporate Overview September 2013 OTCQB: LCDX

2. Slide 2: Caliber I.D. Safe Harbor Statement

   Caliber I.D. Safe Harbor Statement This presentation contains statements about Lucid, Inc. operating as Caliber Imaging & Diagnostics or Caliber I.D. future expectations, plans and prospects that constitute forward-­‐looking statements within the meaning of Section 27A of the Securities Act of 1933,

3. Slide 3: Corporate Snapshot

   Corporate Snapshot Caliber I.D. (LCDX) § Focused on disruptive, non-­‐invasive, point-­‐of-­‐ care cellular imaging technologies § Potential to signiUicantly improve patient outcomes while simultaneously reducing costs § VivaScope® provides physicians with a powerful tool to assist in diagnosis §

4. Slide 4: Experienced Leadership Team

   Experienced Leadership Team § More than 20 years of experience § More than 24 years of optical and advising, analyzing and managing in medical device design, including technology driven companies medical image transfer and storage systems management § Leadership positions at American Aerogel, Con

5. Slide 5: Investment Thesis

   Investment Thesis § Proprietary, Cutting-­‐Edge Platform Imaging Technology § A disruptive, non-­‐invasive, point-­‐of-­‐care platform imaging technology with numerous applications in both dermatology and surgery § Supported by more than 300 independently sponsored studies or publications § FDA

6. Slide 6: Background

   Background 6

7. Slide 7: Core Opportunity: Skin Cancers

   Core Opportunity: Skin Cancers § Prevalent, Treatable Cancers § 1 in 5 (20%) of Americans will develop skin cancer § Melanoma accounts for 75% of all skin cancer deaths, but is 95% curable if diagnosed early § Non-­‐melanoma skin cancer accounts for 3.5M cancer diagnoses annually, 2.5 times the

8. Slide 8: Your Eyes Can Deceive You…

   Your Eyes Can Deceive You… § Standard-­‐of-­‐Care: Visual Inspection § Low accuracy § Frequent misdiagnosis § ABCDE Guidelines § A: Symmetry § B: Border § C: Color Visually, which of these § D: Diameter § E: Evolving abnormalities is malignant § Suspicious lesions are biopsied and which is

9. Slide 9: …and Can Lead to Inaccurate Results

   …and Can Lead to Inaccurate Results Malignant Melanoma Benign Mole A conventional diagnostic approach would have biopsied the benign mole and ignored the malignant melanoma. 9

10. Slide 10: … and Algorithms Can Be Misleading

    … and Algorithms Can Be Misleading FDA Panel Divided on MELA Science’s MelaFind … “At the meeting, the FDA's General and Plastic Surgery Devices Panel voted 8 to 7 with 1 abstention that the data available supported approval” … <of> … “software that uses algorithms to analyze the image, indicating w

11. Slide 11: VivaScope® Cellular Imaging Technology

    VivaScope® Cellular Imaging Technology 11

12. Slide 12: Our Proprietary Technology

    Our Proprietary Technology Pinhole and Detector § Confocal Cellular Imaging § Creates layer-­‐by-­‐layer scans of living tissue, with a >0.2mm imaging depth § Provides a microscopic view of living cells in the skin, with a 3-­‐5 micron cellular resolution, comparable to Laser histology Scanning O

13. Slide 13: Product Portfolio

    Product Portfolio Video In-­‐Vivo Cellular Imager In-­‐Vivo Cellular Imager Telepathology Dermoscopy VivaCam ® VivaScope® 3000 VivaScope® 1500 VivaNet ® /VivaLAN FDA 510(k) cleared FDA 510(k) cleared FDA 510(k) cleared FDA Class 1 Device 13

14. Slide 14: VivaScope® Confocal Imagers

    VivaScope® Confocal Imagers Benign Mole Basal Cell Carcinoma § Images can be interpreted by the physician at the bedside; and/or § Images can be transferred securely to a pathologist on our private network for remote diagnosis Melanoma Squamous Cell Carcinoma 14

15. Slide 15: High Sensitivity and Specificity

    High Sensitivity and SpeciUicity Study Type Number of Lesions Sensi8vity Specificity BCC 152 100% 71% Melanoma 102 97% 72% Melanoma 351 91% 69% Melanoma and Benign 98% w/ dermoscopy 326 68% Nevi 91% standalone BCC: 100% BCC: 89% Melanoma and BCC 710 Melanoma: 88% Melanoma: 71% “Gold Standard” Agreeme

16. Slide 16: Robust Intellectual Property

    Robust Intellectual Property Latest Expira8on US Europe Pacific Rim Patent Type Based on Issued Issued/Pending Issued / Pending /Issued Pending Patents Imaging system technology 26/3 1/5 3/3 Jul-­‐22 In-­‐vivo and ex-­‐vivo disease screening, diagnosis, treatment 25/4 3/8 5/2 Nov-­‐20 and therapy mon

17. Slide 17: Benefits of Using VivaScope® Technology

    BeneUits of Using VivaScope® Technology 17

18. Slide 18: Traditional Care Path

    Traditional Care Path Referral to Dermatologist & Transport Tissue & Read Slide & Ini8al Examina8on Biopsy Prepare the Slide Dictate Report Physician Office Office Visit Pathology Lab Pathology Lab 5-­‐10 minutes 5-­‐30 minutes 2-­‐4 days 2-­‐4 days Expensive and Time-­‐Consuming Diagnos8c Process 18

19. Slide 19: VivaScope® Care Path

    VivaScope® Care Path Physician Immediately Shares Diagnosis with Pa8ent Ini8al Examina8on Confocal Imaging Procedure Image and Report Stored in Cloud Discussion 1-­‐5 minutes Images Transferred Images Interpreted via VivaNet by Pathologist VivaNet Transfer Physician Office 0-­‐3 minutes Imaging Proces

20. Slide 20: Provides Widespread Benefits

    Provides Widespread BeneUits Investors • Par8cipa8on in a fast-­‐growing, high-­‐margin industry • Opportunity to invest early in a proven and ground-­‐ breaking technology Physicians Payers • Improved diagnosis Pa8ents • Significant cost savings by • Be9er pa8ent care • Non-­‐invasive, point-­‐of-­‐

21. Slide 21: Growth Strategy

    Growth Strategy 21

22. Slide 22: VivaScope® is Approved Worldwide…

    VivaScope® is Approved Worldwide… " c o p e is: s Viva The r use " d fo Canada" Russia" " rove "App United States" Europe" " Israel" Korea" " ding " Turkey" "Pen istration China" eg "re-r Brazil" Australia" “No other method allows a comparably fast, painless, and reliable diagnosis of various malign

23. Slide 23: … and Has Global Distribution

    … and Has Global Distribution Distributor Territory Europe/ Mavig GmbH Mid-­‐East Emdutos Brazil Canada Integral Japan Equipmed Australia United States Europe ConBio China China Japan Shin Chen Taiwan Instrument Brazil True Systems South Korea Australia Filtech Enterprise Thailand North Direct Ameri

24. Slide 24: Sales & Marketing Priorities

    Sales & Marketing Priorities Ac8ve projects with major corpora8ons ongoing in each category 2015 2014 2013 2012 Intraopera8ve 2011 Skin Cancer Therapeu8c Screening Monitoring Pathology Development R&D Sales • HMOs • SRT • Head and Neck • ACOs • Brachytherapy • Oral • IHNs • PDT • Cervical • Breast I

25. Slide 25: Adopted by Leading Companies

    Adopted by Leading Companies § Our current customers include some of the most well-­‐respected Fortune 500 companies, academic ins8tu8ons and private prac8ces. § Over 300 units shipped into commercial research and academia markets and 125 units placed into dermatologists offices worldwide. Clinical

26. Slide 26: VivaScope® Comparative Economics

    VivaScope® Comparative Economics Tradi8onal Biopsy Procedure Confocal Imaging $120 Biopsy or Confocal Imaging $120 $125 Pathology/Reading Fees $50 $110 Follow-­‐up Care Costs -­‐ $355 Total Cost per Pa8ent $170 12 Million+ Annual Biopsies or Confocal Imaging $4.3 Billion Total Annual Cost Given that

27. Slide 27: VivaScope® Comparative Economics

    VivaScope® Comparative Economics Procedure Standard-­‐of-­‐Care VivaScope® Biopsy $120 $120 or less Pathology / Reading Fees $130 Op8onal Follow-­‐Up Care Costs $110 Unnecessary Total Cost per Pa8ent $360 $120 or less 1/3rd the Cost Annual Biopsies ~12 Million ~2.4 Million Total Annual Cost $4.3 Bil

28. Slide 28: Numerous Upcoming Catalysts

    Numerous Upcoming Catalysts ü Launched video dermoscopy product § Con8nue process of obtaining ü Secured regulatory approval in Australia reimbursement codes (one of the largest markets) and Brazil § Launch new compact confocal imaging ü Iden8fied immediate revenue device leveraging novel techno

29. Slide 29: Opportunities Beyond Dermatology

    Opportunities Beyond Dermatology § Ongoing technical feasibility studies in Neuropathy, Cervical, Breast, Colon, Prostate cancers Technical Pilot Indica8on Feasibility Accuracy § Na8onal Cancer Ins8tute ongoing study § European VivaNet study Oral ✓ ✓ § 2500 Study for excised 8ssues in the OR Hea

30. Slide 30: Conclusion

    Conclusion § Proprietary, Cutting-­‐Edge Platform Imaging Technology § A disruptive, non-­‐invasive, point-­‐of-­‐care platform imaging technology with numerous applications in both dermatology and surgery § Supported by more than 300 independently sponsored studies or publications § FDA 510(k)

Caliber Imaging & Diagnostics — Investor Presentation (September 2013) on 6ix